Linagliptin ameliorates albuminuria and kidney hypertrophy in DBA/2J diabetic mice but not in G6PD^- mice at 12 weeks.

(A, B): Urine albumin/Creatinine Ratio (ACR) in DBA/2J (A) or in C3H WT and G6PD^- (B), with or without linagliptin treatment as indicated. Spot urine was collected 2 days before sacrifice. Urine albumin and creatinine were measured. Urine ACR was significantly decreased in the DBA/2J linagliptin group (A). There was a trend of decreasing of urine ACR in WT-DM+Lina group (p = 0.088), but there was no change in G6PD deficient diabetic mice treated with linagliptin (B). (C,D): Kidney/body weight ratio in DBA/2J (C) or in C3H WT and G6PD^- (D), with or without linagliptin treatment as indicated. Kidney/body weight ratio was decreased significantly in DBA/2J (C) but increased significantly in G6PD^- (D). * p<0.05, ** p<0.0001 (n = 3–10, mean ± SD, t test).